All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article Open Access

Short Review on Dapagliflozin


Dapagliflozin is a medication of the gliflozin class, used to treat type 2 diabetes. It was produced by Bristol-Myers Squibb in organization with AstraZeneca. Dapagliflozin is a sodium-glucose cotransporter 2(SGLT2) inhibitor. It works by diminishing the measure of sugar the body assimilates and expanding the measure of sugar that leaves the body. Dapagliflozin is utilized alongside diet and work out, and now and again with different drugs, to lower glucose levels in patients with type 2 diabetes (condition in which glucose is too high in light of the fact that the body does not create or utilize insulin ordinarily). Dapagliflozin is in a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It brings down glucose by creating the kidneys to dispose of more glucose. Dapagliflozin is not used to treat type 1 diabetes (condition in which the body does not deliver insulin and, in this manner, can't control the measure of sugar in the blood) or diabetic ketoacidosis (a genuine condition that may create if high glucose is not treated).

Vishnu Vardhan

To read the full article Download Full Article | Visit Full Article